Home / Letter From The Editor / Dec. 9, 2017

Dec. 9, 2017

Dec 9, 2017

For many years cardiovascular disease has been the number one cause of death among diabetes patients. So getting a CV benefit from diabetes drugs is a definite plus. Over the past few weeks Dr. Aaron Vinik has been sharing his views on the values of Cycloset for both diabetes and heart failure.

This week we have a feature that looks at another class of drugs, the SGLT-2 Inhibitors, and multiple studies showing their value in cardiovascular disease prevention.



We can make a difference!


Dave Joffe